中源协和(600645.SH)全资子公司获得药物临床试验批准通知书

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is a cryopreserved cell preparation developed by the company, derived from selected healthy newborn umbilical cord tissue through in vitro separation, expansion, harvesting, and freezing [1] - The clinical indication for VUM02 injection is being expanded to include the treatment of severe/critical pneumonia [1]